{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T07:52:05Z","timestamp":1774597925837,"version":"3.50.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Renin\u2013angiotensin system inhibitors (RASi), including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, improve outcomes after acute myocardial infarction. However, in the drug-eluting stent (DES) era with routine percutaneous coronary intervention (PCI), the duration and timing of benefit after ST-elevation myocardial infarction (STEMI) remain uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Using the nationwide prospective Korea Acute Myocardial Infarction Registry\u2013National Institutes of Health Registry, we identified STEMI patients who underwent successful DES-PCI and survived to discharge (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 5017). RASi exposure was defined at discharge for analyses from 0 to 12 months and reassigned at a 12-month landmark for analyses from 12 to 36 months, reflecting real-world switching or discontinuation. The primary outcome was all-cause mortality. Confounding was addressed using 1 : 1 propensity-score matching (851 pairs) and Cox proportional hazards models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At discharge, 4093 patients received RASi and 924 did not. At 12 months, all-cause mortality was lower with RASi in the overall cohort [2.1 vs. 4.5%, hazard ratio: 0.45, 95% confidence interval (CI): 0.31\u20130.66,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001] and matched cohort (3.0 vs. 4.9%, hazard ratio: 0.61, 95% CI: 0.37\u20131.00,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.050), driven by fewer cardiac deaths. Over 36 months, RASi was associated with lower mortality overall and after matching. From 12 to 36 months, landmark analyses showed neutral associations. First-year left ventricular ejection fraction and blood pressure improved more with RASi (both\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In STEMI treated with DES-PCI, RASi at discharge offers a survival benefit concentrated within the first year. After 12 months, associations were neutral among event-free survivors, supporting early initiation and maintenance of RAS inhibition with individualized reassessment beyond 1 year.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mca.0000000000001622","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:00:15Z","timestamp":1770652815000},"page":"167-178","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing duration of renin\u2013angiotensin system inhibition after ST-elevation myocardial infarction with drug-eluting stent\u2013percutaneous coronary intervention: Real-World Landmark Evidence from the Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry"],"prefix":"10.1097","volume":"37","author":[{"given":"Byoung Geol","family":"Choi","sequence":"first","affiliation":[{"name":"Department of Biomedical Laboratory Science, Honam University, Gwangju"},{"name":"Cardiovascular Intervention Research Institute, Seoul"},{"name":"Department of Cardiology, Gwangju Christian Hospital, Gwangju"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hae Don","family":"Kim","sequence":"additional","affiliation":[{"name":"School of Health and Environmental Science, Korea University, Seoul"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Woon","family":"Rha","sequence":"additional","affiliation":[{"name":"Cardiovascular Intervention Research Institute, Seoul"},{"name":"Cardiovascular Center, Korea University Guro Hospital, Seoul"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Uk","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Gwangju Christian Hospital, Gwangju"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soohyung","family":"Park","sequence":"additional","affiliation":[{"name":"Cardiovascular Intervention Research Institute, Seoul"},{"name":"Cardiovascular Center, Korea University Guro Hospital, Seoul"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manda Satria","family":"Chesario","sequence":"additional","affiliation":[{"name":"Cardiovascular Intervention Research Institute, Seoul"},{"name":"Cardiovascular Center, Korea University Guro Hospital, Seoul"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melly","family":"Susanti","sequence":"additional","affiliation":[{"name":"Cardiovascular Intervention Research Institute, Seoul"},{"name":"Cardiovascular Center, Korea University Guro Hospital, Seoul"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheol Won","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Laboratory Science, Honam University, Gwangju"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheol Ung","family":"Choi","sequence":"additional","affiliation":[{"name":"Cardiovascular Intervention Research Institute, Seoul"},{"name":"Cardiovascular Center, Korea University Guro Hospital, Seoul"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung Ho","family":"Jeong","sequence":"additional","affiliation":[{"name":"Chonnam National University Hospital, Gwangju"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Joo","family":"Oh","sequence":"additional","affiliation":[{"name":"Cardiovascular Intervention Research Institute, Seoul"},{"name":"Department of Cardiology, Naeun Hospital, Incheon, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"R1-20260327","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"R2-20260327","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes.","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"R3-20260327","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"R4-20260327","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJM199501123320203","article-title":"The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators.","volume":"332","author":"Ambrosioni","year":"1995","journal-title":"N Engl J Med"},{"key":"R5-20260327","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.","volume":"333","author":"K\u00f8ber","year":"1995","journal-title":"N Engl J Med"},{"key":"R6-20260327","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"R7-20260327","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"R8-20260327","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"R9-20260327","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"R10-20260327","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"R11-20260327","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting-enzyme inhibition in stable coronary artery disease.","volume":"351","author":"Braunwald","year":"2004","journal-title":"N Engl J Med"},{"key":"R12-20260327","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJMoa0801485","article-title":"Drug-eluting or bare-metal stents for acute myocardial infarction.","volume":"359","author":"Mauri","year":"2008","journal-title":"N Engl J Med"},{"key":"R13-20260327","doi-asserted-by":"crossref","first-page":"994419","DOI":"10.3389\/fcvm.2022.994419","article-title":"Long-term use of renin-angiotensin-system inhibitors after acute myocardial infarction is not associated with survival benefits: analysis of data from the Korean Acute Myocardial Infarction Registry-National Institutes of Health Registry.","volume":"9","author":"Park","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R14-20260327","doi-asserted-by":"crossref","first-page":"g6650","DOI":"10.1136\/bmj.g6650","article-title":"Angiotensin receptor blocker in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function: prospective cohort study.","volume":"349","author":"Yang","year":"2014","journal-title":"BMJ"},{"key":"R15-20260327","doi-asserted-by":"crossref","first-page":"e0242314","DOI":"10.1371\/journal.pone.0242314","article-title":"The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension.","volume":"15","author":"Her","year":"2020","journal-title":"PLoS One"},{"key":"R16-20260327","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12872-021-02070-x","article-title":"Impact of renin angiotensin system inhibitor on 3-year clinical outcomes in acute myocardial infarction patients with preserved left ventricular systolic function: a prospective cohort study from Korea Acute Myocardial Infarction Registry (KAMIR).","volume":"21","author":"Kim","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"R17-20260327","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s00380-023-02244-x","article-title":"The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in elderly (\u2265 65) patients with acute myocardial infarction without hypertension.","volume":"38","author":"Ahn","year":"2023","journal-title":"Heart Vessels"},{"key":"R18-20260327","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.atherosclerosis.2018.08.038","article-title":"Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention.","volume":"277","author":"Byun","year":"2018","journal-title":"Atherosclerosis"},{"key":"R19-20260327","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3349\/ymj.2016.57.1.180","article-title":"Impact of angiotensin converting enzyme inhibitor versus angiotensin receptor blocker on incidence of new-onset diabetes mellitus in Asians.","volume":"57","author":"Park","year":"2016","journal-title":"Yonsei Med J"},{"key":"R20-20260327","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction.","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"R21-20260327","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jacc.2015.07.018","article-title":"Long-term use of cardiovascular drugs: challenges for research and for patient care.","volume":"66","author":"Rossello","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R22-20260327","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1016\/j.jacc.2015.10.023","article-title":"Statistical controversies in reporting of clinical trials: part 2 of a 4-part series on statistics for clinical trials.","volume":"66","author":"Pocock","year":"2015","journal-title":"J Am Coll Cardiol"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T07:00:18Z","timestamp":1774594818000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001622","relation":{},"ISSN":["0954-6928","1473-5830"],"issn-type":[{"value":"0954-6928","type":"print"},{"value":"1473-5830","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"2025-10-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}